Good science needs more than a lab to reach patients.
We work with research teams and early-stage therapeutics and health AI companies to win funding, run the programs that funding pays for, and build the data and analytics behind the science. The PI leads the research. We handle what surrounds it.
Stellar Venture Partners runs its life sciences incubator out of Florida and its technology incubator out of Maryland. Each one sits where its work is, and both share the same leadership, data scientists, and funding strategy.
Therapeutics, diagnostics, and clinical AI. Florida puts us close to the companies we support, the state's university incubators, and its cancer research funding programs. The Life Sciences Incubator is based in Port Orange, Florida.
Stellar iDea Labs builds AI and data platforms for government and commercial markets. The same engineers and data scientists supply the predictive analytics and research data infrastructure our life sciences companies depend on.
Visit the Technology IncubatorMost early-stage life sciences companies have the science and not much else. We fill the gap, from pursuing a grant through running the program it funds.
We review state and federal health research funding announcements and advise on eligibility, compliance requirements, and competitive positioning before a team commits to a pursuit.
Capture management, drafting and review of application components, budget and justification support, and structuring the teaming, partner, and staffing arrangements a program requires.
After award, we provide program oversight, project management, and milestone and deliverable tracking, and we coordinate staffing and subject matter experts so the research team can stay on the research.
We serve as administrative coordinator for reporting. We review draft progress reports against the grant agreement, track obligations, flag gaps early, and keep a complete administrative record.
Analysis of cancer genomic datasets to prioritize mutation subtypes and stratify patient populations and tumor histologies, so programs pick the right models and the right patients.
One queryable research environment that brings together imaging, molecular readouts, and sequencing outputs from preclinical and in-vivo studies, in place of scattered files and spreadsheets.
The principal investigator keeps full control of scientific content and research direction. Our role is administrative, operational, and analytical.
Much of our compensation depends on the company's success, including equity and fees paid as funding arrives. We do well when our partners do.
We are engaged on expertise alone. Every engagement is written to meet funding program rules on procurement integrity, conflicts of interest, and state ethics law.
Bacteria that live in and around tumors, including Fusobacterium nucleatum, Helicobacter pylori, and several Mycoplasma species, release a chaperone protein called DnaK. Bacterial DnaK lowers p53, the protein that stops a damaged cell from dividing. Cisplatin and 5-FU depend on p53 to work. Take p53 away and the drugs lose their leverage.
DnaK Therapeutics is building a drug that blocks the protein and a test that finds the patients who need it.
Small molecules that inhibit bacterial DnaK, given alongside the chemotherapy a patient already receives.
A test that measures how much bacterial DnaK a patient carries, so the therapy goes to the people who have the protein.
DnaK Therapeutics is a preclinical company. Findings to date are from cell-culture and animal studies. Its therapeutic and diagnostic candidates are investigational, have not been tested in humans, and are not approved by the FDA or any other regulator.
The opioid crisis has claimed more than 500,000 lives in the United States over the past two decades, and the standard response is reactive. Most EHR systems flag patients after an overdose or a diagnosis. By then the window for prevention has closed.
Stellar SOAP uses machine learning to identify patients at elevated risk of opioid use disorder months before a crisis would typically present, by finding the behavioral, clinical, and demographic signals that predict risk in combination. Clinicians still make the call.
We are looking for health systems and payers to pilot Stellar SOAP against their patient populations. Talk to us about data integration requirements and pilot structure.
Discuss a PilotIf you are a researcher, university, or early-stage life sciences company with a funding opportunity ahead of you, we want to talk.